| Literature DB >> 30837497 |
Shir Raibman Spector1, Haim Mayan1,2,3, Ronen Loebstein2,3, Noa Markovits2,3, Eldar Priel1, Eias Massalha1, Yuval Shafir1, Itai Gueta4,5.
Abstract
5-oxoprolinemia (pyroglutamic acid, PGA) in the absence of acetaminophen use has been rarely reported as a cause for high anion gap metabolic acidosis. We investigated the prevalence and risk factors for elevated PGA concentrations among hospitalized patients with high anion gap metabolic acidosis: We prospectively enrolled patients with high anion gap metabolic acidosis hospitalized in the department of medicine. For each patient we collected the main diagnosis, concurrent medications and laboratory parameters. Spot urine samples were tested for PGA concentration. Levels ≥63 µmol/mmol creatinine were considered elevated. Overall, forty patients were prospectively followed. Mean age was 66.9 (17.9) years. Four (6.3%) patients had a high urine PGA level and demonstrated also lower blood pH (7.2 vs 7.3, p = 0.05) and lower serum lactate concentration (17.5 mg/dl vs 23.0 mg/dl, p = 0.04). Additionally, the high PGA level group consisted of more patients with septic shock [2/4 (50%) vs 3/36 (8.3%)] with a trend towards significance (p = 0.07). In conclusion, PGA might have a role in patients with septic shock and acidosis. Being a treatable condition, PGA should be taken into consideration particularly when no other cause for high anion gap is identified.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30837497 PMCID: PMC6400893 DOI: 10.1038/s41598-019-39257-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Urinary pyroglutamic acid concentrations and concomitant plasma anion gap.
Univariate analysis of the association between the patient baseline characteristics and low and high pyroglutamic acid concentration.
| Normal range | Low PGA group | High PGA group | P value | |
|---|---|---|---|---|
| Pyroglutamate, µmol/mmol creatinine (SD) | ≤63 | 28.6 (12.3) | 81.3 (24.2) | |
| N | — | 36 | 4 | |
| Age, years (IQR) | — | 68.0 (60.0–80.3) | 52.5 (44.3–84.8) | 0.28 |
| Female (%) | — | 17 (47.2) | 2 (50) | 1.0 |
| Diabetes mellitus type 2 (%) | — | 18 (50) | 1 (25) | 0.61 |
| Chronic renal failure (%) | — | 16 (44.4) | 2 (50) | 1.0 |
| Dialysis (%) | — | 3 (8.3) | 0 (0) | 1.0 |
| Acute renal failure (%) | — | 5 (13.9) | 0 (0) | 1.0 |
| Sepsis (%) | — | 16 (44.4) | 4 (100) | 0.11 |
| Shock (%) | — | 3 (8.3) | 2 (50) | 0.07 |
| RBC x106/ml | 4.2–6.1 | 3.9 (3.7–4.7) | 3.2 (2.9–3.4) | 0.16 |
| Hb, g/dl (SD) | 12–16 | 10.9 (2.9) | 9.4 (1.3) | 0.30 |
| Creatinine mg/dl (IQR) | 0.8–1.3 | 1.7 (0.8–4.2) | 3.1 (1.0–4.5) | 0.65 |
| Urea mg/dl (IQR) | 17–43 | 87.0 (45.3–153.6) | 184.0 (63.8–199.2) | 0.26 |
| pH | 7.35–7.45 | 7.3 (7.3–7.4) | 7.2 (7.0–7.3) | |
| Bicarbonate mmol/l (SD) | 22–26 | 20.2 (4.3) | 18.0 (4.2) | 0.30 |
| Anion Gap meq/l, Figge (SD) | 12–16 | 22.7 (3.1) | 24.3 (2.8) | 0.34 |
| Urine positive for ketones (%) | 0 | 7 (19.4) | 0 (0) | 1.0 |
| Lactate mg/dl (IQR) | 4–16 | 23.0 (17.5–31.5) | 17.5 (10.0–19.0) | |
| Patients received paracetamol (%) | — | 5 (13.9) | 1 (25) | 0.50 |